65 results about "Cervical lesion" patented technology

In certain aspects, the invention relates to methods of diagnosing cervical cancer by using a combination of certain biomarkers such as hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length. In other aspects, the invention relates to methods of detecting immortalization of cervical cells by using a combination of certain biomarkers. In yet other aspects, the invention relates to methods of classifying the grade of a cervical lesion for diagnostic and prognostic purposes in a female. In further aspects, the invention relates to methods of treating cervical cancer by administering a therapeutic agent that targets one or more of these biomarkers.

The present invention provides a method and a kit for determining whether a head and neck cancer is HPV-related. In one embodiment, an RNAscope® HPV assay was designed to detect the presence of E6 / E7 mRNA of certain high-risk HPV subtypes related to head and neck cancer. The present invention also provides a method and a kit for determining whether a cervical lesion is a benign lesion or a cervical intraepithethial neoplasm lesion. The present invention further provides a method for determining the progression of cervical intraepithethial neoplasm based on the spatial pattern and levels of the E6 / E7 mRNA of certain high-risk HPV subtypes. The present invention also provides a method for determining the risk of developing cervical cancer in a human diagnosed with cervical intraepithethial neoplasm based on presence and absence of the certain subgroups of high-risk HPV subtypes.

Provided are methods of isolating RNA from a biological sample, methods and means for determining the presence of particular RNA splice-form variants in a biological sample, methods and means for determining the relative ratio of RNA ratios in a biological sample, and methods and means for predicting the progression of precancerous cervical lesions.

In certain aspects, the invention relates to methods of diagnosing cervical cancer by using a combination of certain biomarkers such as hTERT, IGFBP-3, transferrin receptor, beta-catenin, Myc-HPV E6 interaction, HPV E7, and telomere length. In other aspects, the invention relates to methods of detecting immortalization of cervical cells by using a combination of certain biomarkers. In yet other aspects, the invention relates to methods of classifying the grade of a cervical lesion for diagnostic and prognostic purposes in a female. In further aspects, the invention relates to methods of treating cervical cancer by administering a therapeutic agent that targets one or more of these biomarkers.

The invention provides a monoclonal rabbit antibody for identifying HPV16 positive cervical tissues. The antibody can be used for specifically detecting a biomarker HPV16E7 protein in tissues including cervical cancer and cervical lesions, so that HPV persistent infection related cervical cancer tissues from abnormal or noncancerous cervical epithelial tissues, cervical cancer caused by high-risk HPV infection can be accurately diagnosed, and risk early-warning can be especially performed for whether early cervical lesions cancerate or not, so that the misdiagnosed rate of cervical lesions can be effectively reduced, and injuries and resource waste caused by over treatment for patients can be improved.

The invention is in the field of medicine and is concerned with a molecular diagnostic marker for progression to invasiveness of HPV-induced premalignant lesions and future metastatic potential of HPV-induced premalignant lesions and carcinomas. In particular the present invention relates to the use of the TSLC1 gene as marker for progression to invasive cervical cancer and metastatic potential of cervical lesions. The invention provides methods for detecting HPV-induced invasive cancers and their precursor lesions associated with tumor suppressor lung cancer 1 (TSLC1), comprising contacting a target cellular component of a test cell with a reagent that detects TSLC1 and detecting a reduction in the TSLC1 as compared to that of a comparable normal cell. The invention also provides molecular diagnostic markers for premalignant cervical lesions with invasive potential associated with tumor suppressor lung cancer 1 (TSLC1) in cytologically abnormal cervical smears and / or biopsies.

The invention discloses a kit for detecting sulfydryl metabolite in urine prompting the cervical lesion and a preparation method thereof. The kit comprises a reference agent, a testing agent and a color developing agent, wherein the reference agent is a mercuric chloride solution or a mercury sulfate solution, and the color developing agent is a phosphotungstic acid reagent; the kit is prepared in a sterility packaging manner. The remarkable increment of sulfydryl metabolite in female urine is proved to prompt the cervical lesion. The kit can detect the content of the sulfydryl metabolite at a preclinical phase and a clinical phase, the positive rate and accuracy for detecting the cervical cancer are high, the missed diagnosis can be avoided, a subject is prevented from being wounded and crossly infected, and instruments and equipment are not needed; the detection process is simple, the acceptance of the subject is high, the manpower and material resource can be greatly saved, workload of the examination personnel can be remarkably alleviated, the bottleneck that the screening number cannot reach the standard can be effectively broken through, and the kit is particularly suitable for surveying the cervical cancer in a wide range.

The invention discloses a clinical decision-making system and method for cervical lesions. The clinical decision-making system comprises: a terminal acquisition module for acquiring case data of a patient; an input conversion module for extracting the case data of the patient and converting into characteristic variables; a data processing module for respectively performing discretization, sparse coding and binarization processing on the characteristic variables; a prediction module for outputting prediction results after the processed characteristic variables are subjected to weight and offsetdimension assignment processing, rectification function relu transformation and softmax regression operation; a conformation and diagnosis module for confirming final clinical diagnosis results and providing true labels for the prediction results; a data center module for receiving and storing all case data of the patient and periodically iterating the prediction module based on all data; and a display module for displaying the prediction results, the diagnosis results and health guidance advice. The clinical decision-making system and method provided by the invention can improve specificityand accuracy of a current cervical cancer screening strategy, and realize big data sharing and integrated network management of cervical cancer screening.

The invention discloses a molecular marker for early screening cervical cancer and detecting primers. The molecular marker is a molecular marker JAM3-M4 with the nucleotide sequence as follows: SEQ ID No.1; and the sequences of the primers are as follows: the forward primer of JAM3-M4 has the sequence as shown in SEQ ID No.6, and a reverse primer of JAM3-M4 has the sequence as shown in SEQ ID No.7. The invention firstly finds that the methylation degree of the M4 position of a JAM3 gene is related to cervical lesion, so that the molecular marker can be used for early screening cervical cancer. The invention also discloses the primers and a kit for detecting the molecular marker for early screening cervical cancer.

The present invention provides a technology and a method for preparing a high-throughput exfoliated cell chip. According to the present invention, a cervix brush is adopted to collect cervix exfoliated cells of 26 cervical lesions patients and are immediately placed into a cell preservation solution, centrifugation is performed, the supernatant is removed, a cell immobilization solution is added to immobilize cell precipitate, dehydration transparency and dipping in wax are performed, a tissue chip instrument is adopted to prepare an exfoliated cell paraffin chip and an exfoliated cell paraffin block array, and paraffin slicing is performed to prepare the exfoliated cell chip; and the defect of the conventional cytology detection is overcome, and the prepared exfoliated cell chip can be used for pathological diagnosis, IHC, in situ hybridization and other molecular medicine researches.

The invention discloses a photodynamic therapy system for cervical lesions based on integration of diagnosis and treatment. The system is composed of a three-dimensional mechanical arm. An imaging CCDprobe, a 45-degree 400-nm reflection mirror, a 45-degree 630-nm folding reflection mirror with the reflectivity of 95%, an imaging lens module group, and a light-guide cover. A 400-nm lens and a 400-nm fiber coupling laser device are arranged at the front side of the 45-degree 400-nm reflection mirror; a 630-nm LED profiling array is arranged at the front side of the 45-degree 630-nm folding reflection mirror with the reflectivity of 95% and a power detection lens and a power detection probe are arranged at the rear side; and an infrared temperature-measuring probe is arranged at the right side of the imaging lens module group. According to the invention, real-time detection of the shape, distribution, and dimension of the focus as well as the real-time controllable photodynamic therapy is realized by using the coaxial optical path; the imaging CCD probe is used for collecting the focus image, a computer is used for carrying out image edge detection, and the 630-nm LED profiling arrayis controlled to emit a light spot being same as the focus, so that the precise treatment is realized.

The invention discloses a cervical lesion prediction system based on multi-modal feature level fusion. The system comprises a computer memory, a computer processor and a computer program which is stored in the computer memory and can be executed on the computer processor, a cervical lesion prediction model is stored in the computer memory and comprises an acetic acid image feature extraction network, an iodine image feature extraction network and an auxiliary module used for fusing extracted features. When the computer processor executes a computer program, the following steps are realized: receiving an acetic acid image and an iodine image in colposcopy, and cutting out an area containing cervix uteri; respectively inputting the acetic acid image and the iodine image into an acetic acid image feature extraction network and an iodine image feature extraction network in the cervical lesion prediction model, respectively inputting the acetic acid image and the iodine image into respective auxiliary modules after feature extraction, carrying out feature fusion, and outputting a prediction result through calculation. According to the system, the prediction result can be more accurate so as to assist a doctor in making correct diagnosis and judgment.

The invention discloses a kit and method for methylation detection of cervical lesions and cervical cancer related gene. The kit contains reagents including a PCR reaction solution, eight primers fixed to a PCR octa-tube, a positive reference substance, a negative reference substance and a cell lysate for extracting a sample DNA. The detection method comprises the steps of extracting the sample DNA, processing and purifying the sample DNA, preparing a PCR reaction system and adding the sample, carrying out a PCR amplification reaction, collecting a fluorescence signal, obtaining and analyzingan amplification curve and a melting curve, obtaining a Ct value and a Tm value of each marker by analyzing the amplification curve and the melting curve, formulating a positive determination method based on a weighting algorithm, carrying out positive determination on each marker and integrating, finally explaining sample results. The kit has the advantages of high sensitivity, strong specificityand non-invasiveness, and is particularly suitable for auxiliary diagnosis of cervical high-grade lesions or cervical cancer and HPV-positive shunt management.

The invention provides a biological composition dressing for preventing and treating HPV. The biological composition dressing comprises PHPV protein, carbomer, glycerol, green tea extract and Yujie pure MP components. The biological composition dressing can be prepared in dosage forms of dressing suppository, gel dressing, lotion, film agent and the like. The biological composition dressing has an obvious effect on treating genital tract high-risk HPV infection and lower-level cervical lesions caused by high-risk HPV infection, blocking genital tract HPV infection, improving vaginal micro-environment, relieving vaginal loosening and drying symptoms, reducing vaginal inflammatory reaction and lowering the vaginal PH value.

The invention provides a product for preventing and treating cervical lesions and wounds, comprising an application wall whose inner surface is similar to that of the cervicovaginal portion or / and the surface of the cervical canal. The application wall is loaded with magnetic materials or infrared emitting materials or negative ion emitting materials. At least one kind of material, and the sticking wall can be loaded with medicines for preventing and treating cervical lesions and wounds. The product provided by the invention has the functions of magnetic therapy, infrared therapy, negative ion local cleaning, and targeted drug delivery, and acts on drug molecules through magnetic fields and infrared rays to increase the activity of drug components, improve drug penetration and curative effect. The product of the invention can quickly and thoroughly treat cervical lesions and wounds.

The present invention relates to a method for differentiating in a subject with HPV16 between (i) a severe form of HPV16 infection and (ii) a mild form of HPV16 infection based on determining the amount of a first gene product and a second gene product in a sample of a subject and calculating a ratio of the amount of said first gene product and the amount of said second gene product. Further envisaged by the present invention is a composition comprising an oligonucleotide mixture. Also envisaged by the present invention are a kit and a device adapted to carry out the method of the present invention.

The inventors now have developed a (molecular) diagnostic assay based on detection of alterations in markers MAL and hsa-mi R124, in particular promoter hypermethylation, to identify human papillomavirus (HPV)-induced high-grade precancerous lesions such as premalignant cervical lesions of invasive cervical cancer, within cell material obtained via self-sampling. In particular, the present invention relates to the use of the MAL gene (including its promoter) and the hsa-mi R124 gene as marker for HPV-induced high-grade premalignant lesions, allowing early detection and a better treatment option for the individual patient.

The invention relates to a pillow interior of a medicinal pillow capable of treating cervical spondylosis and a preparation method of the pillow interior. The pillow interior is prepared from the following raw materials in percentage by weight: 20% of notopterygium, 5% of asarum, 5% of chrysanthemum morifolium, 5% of cassia twig, 5% of myrrh, 5% of frankincense, 10% of folium artemisiae argyi, 5% of capsicum annuum, 30% of ligusticum wallichii, 5% of cassia seeds and 5% of divaricate saposhnikovia roots. The traditional Chinese medicine ingredients in percentage by weight are fabricated into cylindrical traditional Chinese medicine blocks through extrusion forming and the weight of each cylindrical traditional Chinese medicine block is 1kg. The pillow interior of the medicinal pillow has the effects of relieving an exterior syndrome, dispelling cold, dispelling the wind, warming the middle warmer, inducing resuscitation, stopping pain, smoothing the liver, improving eyesight, dispersing blood, removing stasis, reducing swelling, promoting granulation, removing dampness, killing insects, lubricating the intestines and relieving convulsion; aroma volatilized from traditional Chinese medicines and a skin texture generate an interactive treatment effect through smell of a patient and cortical infiltration; the medicines penetrate into cervical lesions, dredge qi-blood blockage, form a channel and soften a rigid muscular ligament, so that brain nervus centralis is unblocked, meanwhile, compression stimulation on different nerve roots and blood vessels can be completely released after a vertebral interspace is pulled open, qi and blood meridians circulate normally and the symptoms of acid, numbness, stiffness and pain are eliminated.

The invention relates to a built-in micro-colposcopy. The built-in micro-colposcopy is provided with a support frame, a mechanical arm, a connector, a movable handle, a detection device, an image receiving device, an image transmission device and an image processing terminal. One end of the mechanical arm is connected with the support frame and the other end of the mechanical arm is connected with the connector. The movable handle is fixed at the position, near the detection device, of the mechanical arm. The connector is connected with the mechanical arm and the detection device. The detection device is connected with the image receiving device. The image receiving device is connected with the image processing terminal through the image transmission device. The detection device is provided with an outer shell, an inner shell, a protective cover, a light source box, an image formation assembly, a telescopic assembly and a reflector control assembly. The built-in micro-colposcopy can be arranged inside a vagina, the vagina and cervical tissue can be observed intuitively and closely, and the correct diagnosis of vaginal and cervical lesions is more convenient.

The inventors now have developed a (molecular) diagnostic assay based on detection of alterations in markers MAL and hsa-mi R124, in particular promoter hypermethylation, to identify human papillomavirus (HPV)-induced high-grade precancerous lesions such as premalignant cervical lesions of invasive cervical cancer, within cell material obtained via self- sampling. In particular, the present invention relates to the use of the MAL gene (including its promoter) and the hsa-mi R124 gene as marker for HPV- induced high-grade premalignant lesions, allowing early detection and a better treatment option for the individual patient.

The invention discloses a composition and diagnostic reagent for detecting high-grade cervical lesions and cervical cancer. The composition comprises specific primers for detecting 425, 427 and 438 site methylation of a human EPB41L3 gene, 6367 and 6389 site methylation of a virus HPV 16L1 gene and 4256, 4261, 4265, 4269, 4275 and 4282 site methylation of an HPV18L2 gene, and respective reference primers. According to the composition and diagnostic reagent for detecting the high-grade cervical lesions and cervical cancer, by combining human EPB41L3 and virus HPV 16L1 and HPV18L2 methylation detection, the high-risk HPV virus methylation level serving as the direct pathogenesis of cervical cancer is brought into a detection system for the first time, the sensitivity is high, the specificity is high, and the prediction accuracy of the high-grade cervical lesions and cervical cancer is remarkably improved.

The present invention provides for compositions or formulations including a curcuminoid and at least one of resveratrol, resveratrol derivative, catechin, or catechin derivative. The present invention also provides for a method of treating any disease where uncontrolled cellular proliferation occurs, such as cancers. In particular, the present invention provides a method for treating cervical cancer and precancerous cervical lesions. The present invention also provides methods to treat viral infections. The disclosed compositions or formulations are biologically more active demonstrating strong synergy, functions to activate multiple novel genes. The disclosure further shows that the composition increases cellular uptake of curcumin and are able to stabilize curcumin in an aqueous environment. All these enhanced properties are accomplished by a composition or formulation that is much simpler to manufacture and lower in cost.

The invention is in the field of medicine and is concerned with a molecular diagnostic marker for progression to invasiveness of HPV-induced premalignant lesions and future metastatic potential of HPV-induced premalignant lesions and carcinomas. In particular the present invention relates to the use of the TSLC1 gene as marker for progression to invasive cervical cancer and metastatic potential of cervical lesions. The invention provides methods for detecting HPV-induced invasive cancers and their precursor lesions associated with tumor suppressor lung cancer 1 (TSLC1), comprising contacting a target cellular component of a test cell with a reagent that detects TSLC1 and detecting a reduction in the TSLC1 as compared to that of a comparable normal cell. The invention also provides molecular diagnostic markers for premalignant cervical lesions with invasive potential associated with tumor suppressor lung cancer 1 (TSLC1) in cytologically abnormal cervical smears and / or biopsies.

The present invention relates to a method for improved diagnosis of cervical lesions based on detection of gene products encoded by the INK4a gene locus. According to the present invention an improvement in diagnosis may be achieved by assessing the presence or absence or the level of overexpression of at least two different gene products encoded by the INK4a gene locus. In another aspect the present invention relates to peptides derived from cell cycle regulatory proteins, the expression of which is altered in association with tumors in individuals. These peptides according to the present invention may be used for detection and therapy of tumors. For detection purposes the peptides may for example be used to detect antibodies directed against said peptides. In therapeutic respect the peptides may be used for immunotherapy or vaccination approaches. In therapeutic and diagnostic respect the peptides may be used in combination with one or more peptides derived from tumor associated proteins.

The invention discloses a drug composition for treating the cervical cancer and a preparation method thereof. The drug composition comprises the following raw drugs: honeysuckle, zedoary, forsythia, chilopod, sinkiang arnebia root and amur corktree bark. The preparation method is characterized by firstly extracting the zedoary and the forsythia to obtain volatile oil, preparing the rest raw drugs into powder and mixing the powder with the volatile oil to further process clinically acceptable external preparations including but not limited to suppository, effervescing agents, sprays, aerosol or paste. Pharmacodynamic experiments show the drug composition has remarkable anti-inflammatory effect and boosts cell apoptosis by differentiation-transformation, thus having effect on the SiHa cell of human cervical squamous cell carcinoma. The drug composition can directly inhibit growth of the cervical cancer cells, can achieve the aim of inhibiting tumors by regulating the molecular mechanism of P53 gene expression and is a safe, effective and side-effect-free external traditional Chinese drug preparation for preventing cervical lesions.

The present invention relates to a traditional Chinese medicine composition for treating high-risk subtype cervical HPV persistent infection. The traditional Chinese medicine composition is composed of Lanzugeyou antibacterial liquid and injection water, wherein the volume ratio of the Lanzugeyou antibacterial liquid to the injection water is 2:(0.8-1.1), and the Lanzugeyou antibacterial liquid contains 0.12-0.15% (w / w) of chlorhexidine acetate, herba taraxaci, herba portulacae, radix isatidis, folium isatidis, fructus cnidii, herba equiseti hiemalis, flos carthami, radix et rhizoma rhei, radix sophorae flavescentis and fructus bruceae javanicae. The invention also provides an application of the traditional Chinese medicine composition for treating high-risk subtype cervical HPV persistentinfection. The traditional Chinese medicine composition has the advantages that cervical HPV can be quickly and effectively removed to quickly turn to be negative; after a cervical vaginal low-gradesquamous intraepithelial lesion patient is treated with the traditional Chinese medicine composition, a pathological result can be quickly reversed and the progress in the canceration direction is avoided; and after a cervical high-grade squamous intraepithelial lesion post-operative high-risk subtype HPV persistent infection patient is treated with the traditional Chinese medicine composition, the HPV can be quickly removed to turn to be negative, and the cervical lesion relapse or canceration risk of the patient is remarkably lowered.

The invention provides a monoclonal antibody for recognizing HPV16 positive cervical epithelial cancer cells, and applications thereof, wherein the antibody can specifically detect the cervical cancer biomarker HPV16E7 protein in tumor cells so as to distinguish the cancerous cervical epithelial cells and the cervical abnormality or non-cancerous cervical epithelial cells, such that the basis can be provided for doctors so as to accurately diagnose the cancer caused by HPV infection, the missed diagnosis rate of the high-grade cervical lesion can be effectively reduced, the sufficient time and the basis can be provided for the clinical doctor to diagnose and treat the patients, and the early cervical disease detection and the early intervention can be improved; and with the monoclonal antibody, the unnecessary colposcopy can be reduced and avoided.

The present invention provides a monoclonal antibody capable of recognizing high-risk HPV E7 positive cervical epithelial cancer cells, and applications thereof. According to the present invention, the monoclonal antibody can highly specifically detect cervical cancer biomarkers HPV E7 protein in tumor cells, wherein the cervical cancer biomarker HPV E7 protein covers HPV16, HPV31, HPV35, HPV52 and HPV58 and other high-risk subtypes, such that cancerous cervical epithelial cells and abnormal cervix or non-cancerous cervical epithelial cells can be distinguishes so as to provide basis for the accurate diagnosis of HPV infection-induced cancers, effectively reduce the missed diagnosis of high-grade cervical lesions, provide complete time and complete basis for the diagnosis and the treatmentof patients by clinicians, improve the detection of early-stage cervical diseases and the early intervention, and reduce and avoid unnecessary colposcopy.

The invention belongs to the technical field of medical devices, and discloses a cervical lesion detector which comprises a pressure power device and a detection bar. The pressure power device comprises a holding body, a base hole is formed in the front end of the holding body, a transmission sleeve is arranged in the base hole and rotates relative to the base hole, a wireless pressure sensor is arranged at the bottom of the transmission sleeve, a motor and a main board are arranged in the holding body, the motor is used for driving the transmission sleeve, the main board is used for controlling the motor to run, the detection bar comprises a detection shaft matched with the transmission sleeve, a conical detection head is arranged at the front end of the detection shaft, the rear end of the detection shaft can be inserted into a sleeve, and the pressure is applied to the wireless pressure sensor. According to the detector, a clinician can independently judge and read a result in cervical lesions detection, and the detector is bedside, easy to operate, low in cost, short in time and suitable for popularization and use and solves awkward situations in domestic cervical cancer screening of women.

The invention discloses a drug composition for treating the cervical cancer and a preparation method thereof. The drug composition comprises the following raw drugs: honeysuckle, zedoary, forsythia, chilopod, sinkiang arnebia root and amur corktree bark. The preparation method is characterized by firstly extracting the zedoary and the forsythia to obtain volatile oil, preparing the rest raw drugsinto powder and mixing the powder with the volatile oil to further process clinically acceptable external preparations including but not limited to suppository, effervescing agents, sprays, aerosol or paste. Pharmacodynamic experiments show the drug composition has remarkable anti-inflammatory effect and boosts cell apoptosis by differentiation-transformation, thus having effect on the SiHa cell of human cervical squamous cell carcinoma. The drug composition can directly inhibit growth of the cervical cancer cells, can achieve the aim of inhibiting tumors by regulating the molecular mechanismof P53 gene expression and is a safe, effective and side-effect-free external traditional Chinese drug preparation for preventing cervical lesions.